First Trust Nasdaq Pharmaceuticals ETFの空売り状況は、投資家がFirst Trust Nasdaq Pharmaceuticals ETFの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH), 空売り情報

First Trust Nasdaq Pharmaceuticals ETF

Healthcare

Other

The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depository receipts that comprise the index. The index is designed to provide exposure to U.S. companies comprising the pharmaceutical sector that have been selected based upon their liquidity and weighted based upon their cumulative score on three investing factors: volatility, value and growth. It is non-diversified.

Pfizer, Inc.

Abbvie Inc.

Johnson & Johnson

Bristol-Myers Squibb Co.

Merck & Company, Inc.

United Therapeutic

Amgen Inc.

Nvaesrtex Pharmaceuticals Inc

Regeneron Parmaceuticals Inc.

Gilead Sciences Inc

WIIM

FLYW

Flywire shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 revenue guidance above estimates.

Vor Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VOR#NASDAQ">VOR</a>) reported quarterly losses of $(0.40) per share which met the analyst consensus estimate. This is a 18.37 percent increase over losses of $(0.49) per share from the same period last year.

Earnings

News

Vor Biopharma Q3 EPS $(0.40), Inline

Guidance

Ovintiv Sees FY24 Capital Investment $2.275B-$2.325B

Farmer Bros (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARM#NASDAQ">FARM</a>) reported quarterly losses of $(0.24) per share which met the analyst consensus estimate. The company reported quarterly sales of $85.066 million which beat the analyst consensus estimate of $84.100 million by 1.15 percent. This is a 3.88 percent increase over sales of $81.888 million the same period last year.

Earnings Beats

FARM

Farmer Bros Q1 2025 GAAP EPS $(0.24), Inline, Sales $85.066M Beat $84.100M Estimate

Offerings

CRBG

Corebridge Financial Announces Launch of 30M Share Secondary Offering of Common Stock by AIG

Ovintiv Sees Q4 Capital Investment $525M-$575M

Sweetgreen shares are trading lower after the company reported worse-than-expected Q3 financial results.

GigaCloud Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCT#NASDAQ">GCT</a>) reported quarterly earnings of $0.98 per share which beat the analyst consensus estimate of $0.67 by 46.27 percent. This is a 66.1 percent increase over earnings of $0.59 per share from the same period last year. The company reported quarterly sales of $303.316 million which beat the analyst consensus estimate of $279.570 million by 8.49 percent. This is a 70.24 percent increase over sales of $178.167 million the same period last year.

GigaCloud Tech Q3 2024 GAAP EPS $0.98 Beats $0.67 Estimate, Sales $303.316M Beat $279.570M Estimate

ACVA

ACV Auctions shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 sales guidance.

Karat Packaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRT#NASDAQ">KRT</a>) reported quarterly earnings of $0.47 per share which missed the analyst consensus estimate of $0.52 by 9.62 percent. The company reported quarterly sales of $112.771 million which missed the analyst consensus estimate of $112.933 million by 0.14 percent. This is a 6.86 percent increase over sales of $105.528 million the same period last year.

Earnings Misses

Karat Packaging Q3 2024 Adj. EPS $0.47 Misses $0.52 Estimate, Sales $112.771M Miss $112.933M Estimate

Ovintiv Q3 EPS $1.92

Income Opportunity Realty Q3 EPS $0.29 Down From $0.39 YoY

CARG

CarGurus shares are trading higher after the company reported better-than-expected Q3 financial results and issued FY24 guidance and Q4 adjusted EPS guidance above estimates.

General

NVNI

Nvni Group Limited Receives Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency

EMX Royalty Q3 Sales $7.03M Down From $12.93M YoY

Cardiff Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDF#NASDAQ">CRDF</a>) reported quarterly losses of $(0.25) per share which beat the analyst consensus estimate of $(0.27) by 7.41 percent. This is a 13.64 percent decrease over losses of $(0.22) per share from the same period last year. The company reported quarterly sales of $165.00 thousand which beat the analyst consensus estimate of $80.00 thousand by 106.25 percent. This is a 17.02 percent increase over sales of $141.00 thousand the same period last year.

CRDF

Cardiff Oncology Q3 EPS $(0.25) Beats $(0.27) Estimate, Sales $165.00K Beat $80.00K Estimate

Biotech

ELTX

Elicio Therapeutics Shares ELI-002 Phase 1 Data At SITC 2024; Preliminary Results Show Dose-Dependent T Cell Responses Targeting KRAS Mutations And Link To Disease-Free Survival

Abacus Life (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.14 by 42.86 percent. The company reported quarterly sales of $28.148 million which missed the analyst consensus estimate of $28.461 million by 1.10 percent. This is a 33.27 percent increase over sales of $21.121 million the same period last year.

Abacus Life Q3 2024 Adj. EPS $0.20 Beats $0.14 Estimate, Sales $28.148M Miss $28.461M Estimate

EPRX

Eurpaxia Pharmaceuticals Q3 EPS $(0.17) Up From $(0.18) YoY

CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of $(0.17) by 141.18 percent. The company reported quarterly sales of $33.432 million which beat the analyst consensus estimate of $17.514 million by 90.88 percent. This is a 26.71 percent increase over sales of $26.384 million the same period last year.

CTMX

CytomX Therapeutics Q3 2024 GAAP EPS $0.07 Beats $(0.17) Estimate, Sales $33.432M Beat $17.514M Estimate

First Trust Nasdaq Pharmaceuticals ETF declares quarterly distribution of $0.1218

Comments

First Trust Nasdaq Pharmaceuticals ETF

空売り

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH), 空売り情報

ニュース

パートナーシップ

ベンジンガ・グローバル